Published in Oncoimmunology on July 01, 2012
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol (2016) 2.09
Classification of current anticancer immunotherapies. Oncotarget (2014) 1.55
Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy. Oncoimmunology (2014) 1.22
Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy. J Natl Cancer Inst (2016) 1.11
Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. Oncoimmunology (2015) 1.06
Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 "super-stimulation". Mol Ther (2013) 1.05
Clinical application of genetically modified T cells in cancer therapy. Clin Transl Immunology (2014) 1.03
Trial Watch: Adoptive cell transfer for anticancer immunotherapy. Oncoimmunology (2013) 0.95
Novel immunotherapies for hematologic malignancies. Immunol Rev (2015) 0.90
Smart CARs engineered for cancer immunotherapy. Curr Opin Oncol (2015) 0.88
Strategies and developments of immunotherapies in osteosarcoma. Oncol Lett (2015) 0.86
Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells. ISRN Oncol (2012) 0.84
Immunotherapy of acute leukemia by chimeric antigen receptor-modified lymphocytes using an improved Sleeping Beauty transposon platform. Oncotarget (2016) 0.81
CAR models: next-generation CAR modifications for enhanced T-cell function. Mol Ther Oncolytics (2016) 0.81
Chimeric antigen receptor for adoptive immunotherapy of cancer: latest research and future prospects. Mol Cancer (2014) 0.80
Exploiting IL-17-producing CD4(+) and CD8(+) T cells to improve cancer immunotherapy in the clinic. Cancer Immunol Immunother (2016) 0.79
Chimeric Antigen Receptor T Cells and Hematopoietic Cell Transplantation: How Not to Put the CART Before the Horse. Biol Blood Marrow Transplant (2016) 0.78
Adoptive immunotherapy for acute leukemia: New insights in chimeric antigen receptors. World J Stem Cells (2015) 0.78
An NCR1-based chimeric receptor endows T-cells with multiple anti-tumor specificities. Oncotarget (2014) 0.77
Regression of established renal cell carcinoma in nude mice using lentivirus-transduced human T cells expressing a human anti-CAIX chimeric antigen receptor. Mol Ther Oncolytics (2014) 0.77
PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells. Oncoimmunology (2017) 0.75
Summary of emerging targets in anal cancer: the case for an immunotherapy based-approach. J Gastrointest Oncol (2016) 0.75
Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells. J Hematol Oncol (2017) 0.75
OX40 signaling is involved in the autoactivation of CD4(+)CD28(-) T cells and contributes to the pathogenesis of autoimmune arthritis. Arthritis Res Ther (2017) 0.75
How Chimeric Antigen Receptor Design Affects Adoptive T Cell Therapy. J Cell Physiol (2016) 0.75
Adoptive transfer of murine T cells expressing a chimeric-PD1-Dap10 receptor as an immunotherapy for lymphoma. Immunology (2017) 0.75
Quantitative Imaging Approaches to Study the CAR Immunological Synapse. Mol Ther (2017) 0.75
LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science (2003) 19.77
T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med (2011) 12.58
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med (2008) 11.49
IL-10: the master regulator of immunity to infection. J Immunol (2008) 6.11
Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A (1993) 5.23
Regulatory T cells expressing interleukin 10 develop from Foxp3+ and Foxp3- precursor cells in the absence of interleukin 10. Nat Immunol (2007) 5.14
Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat Rev Immunol (2003) 5.01
Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia (2004) 3.59
A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther (2005) 3.18
Regulatory activity of autocrine IL-10 on dendritic cell functions. J Immunol (2001) 2.89
Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain. J Immunol (2004) 2.49
The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion. J Immunol (2000) 2.04
The PI-3 kinase/Akt pathway and T cell activation: pleiotropic pathways downstream of PIP3. Immunol Rev (2003) 2.02
Ox40-ligand has a critical costimulatory role in dendritic cell:T cell interactions. Immunity (1999) 2.02
Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J Immunol (1998) 1.96
Cloning of mouse Ox40: a T cell activation marker that may mediate T-B cell interactions. J Immunol (1993) 1.51
Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules. Int J Cancer (1997) 1.50
Transfer of autologous gene-modified T cells in HIV-infected patients with advanced immunodeficiency and drug-resistant virus. Mol Ther (2007) 1.44
The role of OX40-mediated co-stimulation in T-cell activation and survival. Crit Rev Immunol (2009) 1.39
CD28-independent costimulation of T cells by OX40 ligand and CD70 on activated B cells. J Immunol (1999) 1.35
4-1BB and OX40 act independently to facilitate robust CD8 and CD4 recall responses. J Immunol (2004) 1.30
Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor. J Immunol (2008) 1.27
Evaluation of OX40 ligand as a costimulator of human antiviral memory CD8 T cell responses: comparison with B7.1 and 4-1BBL. J Immunol (2005) 1.23
Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy. Immunol Res (2011) 1.22
Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells. Clin Cancer Res (2009) 1.15
Building better chimeric antigen receptors for adoptive T cell therapy. Curr Gene Ther (2010) 1.10
Sustained antigen-specific antitumor recall response mediated by gene-modified CD4+ T helper-1 and CD8+ T cells. Cancer Res (2007) 1.06
Redirecting human CD4+CD25+ regulatory T cells from the peripheral blood with pre-defined target specificity. Gene Ther (2009) 1.03
Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28-OX40 signalling. Int J Cancer (2011) 1.01
T-cell activation by recombinant receptors: CD28 costimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptor-mediated target cell lysis. Cancer Res (2001) 1.00
CD28 costimulation Impairs the efficacy of a redirected t-cell antitumor attack in the presence of regulatory t cells which can be overcome by preventing Lck activation. Mol Ther (2011) 1.00
A retroviral vector system 'STITCH' in combination with an optimized single chain antibody chimeric receptor gene structure allows efficient gene transduction and expression in human T lymphocytes. Gene Ther (1998) 0.95
Combination of vaccination and chimeric receptor expressing T cells provides improved active therapy of tumors. J Immunol (2006) 0.90
Retroviral insertional mutagenesis can contribute to immortalization of mature T lymphocytes. Mol Med (2011) 0.88
Humanized anti-carcinoembryonic antigen antibody: strategies to enhance human tumor cell killing. Year Immunol (1993) 0.84
Regulation of the IL-10 production by human T cells. Scand J Immunol (2001) 0.84
Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood (2007) 2.50
T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice. Gastroenterology (2013) 1.77
IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res (2011) 1.33
CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe. Trends Mol Med (2012) 1.32
Eradication of melanomas by targeted elimination of a minor subset of tumor cells. Proc Natl Acad Sci U S A (2011) 1.31
Rational development of high-affinity T-cell receptor-like antibodies. Proc Natl Acad Sci U S A (2009) 1.23
Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas. Proc Natl Acad Sci U S A (2008) 1.18
HLA-G and MIC expression in tumors and their role in anti-tumor immunity. Trends Immunol (2003) 1.17
Regression of metastatic melanoma in a patient by antibody targeting of cancer stem cells. Oncotarget (2012) 1.11
Building better chimeric antigen receptors for adoptive T cell therapy. Curr Gene Ther (2010) 1.10
The complex role of B7 molecules in tumor immunology. Trends Mol Med (2008) 1.09
Redirecting T cells to Ewing's sarcoma family of tumors by a chimeric NKG2D receptor expressed by lentiviral transduction or mRNA transfection. PLoS One (2012) 1.08
Combining cytokine-induced killer cells with vaccination in cancer immunotherapy: more than one plus one? Leuk Res (2011) 1.07
Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells. Prostate (2007) 1.07
Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 "super-stimulation". Mol Ther (2013) 1.05
Do CARs need a driver's license? Adoptive cell therapy with chimeric antigen receptor-redirected T cells has caused serious adverse events. Hum Gene Ther (2010) 1.04
CD28 costimulation overcomes transforming growth factor-beta-mediated repression of proliferation of redirected human CD4+ and CD8+ T cells in an antitumor cell attack. Cancer Res (2007) 1.04
Development of adoptive cell therapy for cancer: a clinical perspective. Hum Gene Ther (2010) 1.03
T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice. Gastroenterology (2012) 1.03
Effective proliferation of human regulatory T cells requires a strong costimulatory CD28 signal that cannot be substituted by IL-2. J Immunol (2007) 1.02
Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28-OX40 signalling. Int J Cancer (2011) 1.01
CD28 costimulation Impairs the efficacy of a redirected t-cell antitumor attack in the presence of regulatory t cells which can be overcome by preventing Lck activation. Mol Ther (2011) 1.00
Depletion of annexin A5, annexin A6, and collagen X causes no gross changes in matrix vesicle-mediated mineralization, but lack of collagen X affects hematopoiesis and the Th1/Th2 response. J Bone Miner Res (2012) 0.99
The proteasome inhibitor bortezomib sensitizes melanoma cells toward adoptive CTL attack. Cancer Res (2010) 0.99
T cell activation by antibody-like immunoreceptors: the position of the binding epitope within the target molecule determines the efficiency of activation of redirected T cells. J Immunol (2007) 0.98
Antigen-Specific T-Cell Activation Independently of the MHC: Chimeric Antigen Receptor-Redirected T Cells. Front Immunol (2013) 0.98
Human CD4+ T cells lyse target cells via granzyme/perforin upon circumvention of MHC class II restriction by an antibody-like immunoreceptor. J Immunol (2006) 0.97
XIAP targeting sensitizes Hodgkin lymphoma cells for cytolytic T-cell attack. Blood (2006) 0.97
Improved activation toward primary colorectal cancer cells by antigen-specific targeting autologous cytokine-induced killer cells. Clin Dev Immunol (2012) 0.95
T cells redirected against hepatitis B virus surface proteins eliminate infected hepatocytes. Gastroenterology (2007) 0.95
Redirected T cells that target pancreatic adenocarcinoma antigens eliminate tumors and metastases in mice. Gastroenterology (2012) 0.94
Chimeric antigen receptors for T-cell based therapy. Methods Mol Biol (2012) 0.92
Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma. Immunol Rev (2014) 0.92
Regulatory T cells with reduced repressor capacities are extensively amplified in pulmonary sarcoid lesions and sustain granuloma formation. Clin Immunol (2011) 0.91
CAR T cells transform to trucks: chimeric antigen receptor-redirected T cells engineered to deliver inducible IL-12 modulate the tumour stroma to combat cancer. Cancer Immunol Immunother (2012) 0.90
Conditions of retinal glial and inflammatory cell activation after irradiation in a GFP-chimeric mouse model. Invest Ophthalmol Vis Sci (2010) 0.90
Adoptive immunotherapy with redirected T cells produces CCR7- cells that are trapped in the periphery and benefit from combined CD28-OX40 costimulation. Hum Gene Ther (2013) 0.89
Simultaneous targeting of IL2 and IL12 to Hodgkin's lymphoma cells enhances activation of resting NK cells and tumor cell lysis. Int J Cancer (2005) 0.87
The CD3-zeta chimeric antigen receptor overcomes TCR Hypo-responsiveness of human terminal late-stage T cells. PLoS One (2012) 0.87
A GMP-compliant protocol to expand and transfect cancer patient T cells with mRNA encoding a tumor-specific chimeric antigen receptor. Cancer Immunol Immunother (2014) 0.87
An IL12-IL2-antibody fusion protein targeting Hodgkin's lymphoma cells potentiates activation of NK and T cells for an anti-tumor attack. PLoS One (2012) 0.86
Interleukin-6 fused to an anti-idiotype antibody in a vaccine increases the specific humoral immune response against CA125+ (MUC-16) ovarian cancer. Cancer Res (2003) 0.85
The beating heart of melanomas: a minor subset of cancer cells sustains tumor growth. Oncotarget (2011) 0.85
TRUCKs: the fourth generation of CARs. Expert Opin Biol Ther (2015) 0.85
Nonviral RNA transfection to transiently modify T cells with chimeric antigen receptors for adoptive therapy. Methods Mol Biol (2013) 0.84
Second mitochondria-derived activator of caspase (SMAC) mimetic potentiates tumor susceptibility toward natural killer cell-mediated killing. Leuk Lymphoma (2013) 0.84
Costimulation tunes tumor-specific activation of redirected T cells in adoptive immunotherapy. Cancer Immunol Immunother (2006) 0.83
T cells engineered with a cytomegalovirus-specific chimeric immunoreceptor. J Virol (2010) 0.83
Of chimeric antigen receptors and antibodies: OX40 and 41BB costimulation sharpen up T cell-based immunotherapy of cancer. Immunotherapy (2013) 0.82
Anti-CD30-IL-12 antibody-cytokine fusion protein that induces IFN-gamma secretion of T cells and NK cell-mediated lysis of Hodgkin's lymphoma-derived tumor cells. Int J Cancer (2003) 0.82
B7/CD28 costimulation of T cells induces a distinct proteome pattern. Mol Cell Proteomics (2005) 0.82
CD7(-) T cells are late memory cells generated from CD7(+) T cells. Rejuvenation Res (2008) 0.82
Survivin blockade sensitizes rhabdomyosarcoma cells for lysis by fetal acetylcholine receptor-redirected T cells. Am J Pathol (2013) 0.82
Interleukin-12 antagonists as new therapeutic agents in inflammatory bowel disease. Pathobiology (2003) 0.81
Young T Cells Age During a Redirected Anti-Tumor Attack: Chimeric Antigen Receptor-Provided Dual Costimulation is Half the Battle. Front Immunol (2013) 0.81
Anti-CD30-scFv-Fc-IL-2 antibody-cytokine fusion protein that induces resting NK cells to highly efficient cytolysis of Hodgkin's lymphoma derived tumour cells. Int J Cancer (2004) 0.80
A proteomic view at T cell costimulation. PLoS One (2012) 0.80
Generation, expression, and monitoring of recombinant immune receptors for use in cellular immunotherapy. Methods Mol Biol (2003) 0.80
Engineered T cells for the adoptive therapy of B-cell chronic lymphocytic leukaemia. Adv Hematol (2011) 0.79
Chimeric antigen receptor T cells: power tools to wipe out leukemia and lymphoma. Expert Rev Hematol (2015) 0.77
Extensive amplification of human regulatory T cells alters their functional capacities and targets them to the periphery. Rejuvenation Res (2008) 0.77
The recombinant T cell receptor strategy: insights into structure and function of recombinant immunoreceptors on the way towards an optimal receptor design for cellular immunotherapy. Curr Gene Ther (2002) 0.77
B7-1 and B7-2 act differentially in the induction of a T cell response: their impact for a HLA-matched and HLA-mismatched anti-tumor immunotherapy. Int J Cancer (2005) 0.76
Targeting two co-operating cytokines efficiently shapes immune responses. Oncoimmunology (2013) 0.76
CAR's made it to the pancreas. Oncoimmunology (2012) 0.75
PECAM1(+)/Sca1(+)/CD38(+) vascular cells transform into myofibroblast-like cells in skin wound repair. PLoS One (2013) 0.75
Antibody-IL2 fusion proteins for tumor targeting. Methods Mol Biol (2012) 0.75